

## Publication

### Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index

#### **JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)**

**ID** 3887537

**Author(s)** Stolz, Daiana; Kostikas, Kostantinos; Blasi, Francesco; Boersma, Wim; Milenkovic, Branislava; Lacoma, Alicia; Louis, Renaud; Aerts, Joachim G.; Welte, Tobias; Torres, Antoni; Rohde, Gernot G. U.; Boeck, Lucas; Rakic, Janko; Scherr, Andreas; Hertel, Sabine; Giersdorf, Sven; Tamm, Michael

**Author(s) at UniBasel** [Boeck, Lucas](#) ;

**Year** 2014

**Title** Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index

**Journal** European Respiratory Journal

**Volume** 43

**Number** 2

**Pages / Article-Number** 397-408

The BODE (body mass index, airflow obstruction, dyspnoea, exercise capacity) index is well-validated for mortality prediction in chronic obstructive pulmonary disease (COPD). Concentrations of plasma pro-adrenomedullin, a surrogate for mature adrenomedullin, independently predicted 2-year mortality among inpatients with COPD exacerbation. We compared accuracy of initial pro-adrenomedullin level, BODE and BODE components, alone or combined, in predicting 1-year or 2-year all-cause mortality in a multicentre, multinational observational cohort with stable, moderate to very severe COPD. Pro-adrenomedullin was significantly associated ( $p<0.001$ ) with 1-year mortality (4.7%) and 2-year mortality (7.8%) and comparably predictive to BODE regarding both (C statistics 0.691 versus 0.745 and 0.635 versus 0.679, respectively). Relative to using BODE alone, adding pro-adrenomedullin significantly improved 1-year and 2-year mortality prognostication (C statistics 0.750 and 0.818, respectively; both  $p<0.001$ ). Pro-adrenomedullin plus BOD was more predictive than the original BODE including 6-min walk distance. In multivariable analysis, pro-adrenomedullin (likelihood ratio Chi-squared 13.0,  $p<0.001$ ), body mass index (8.5,  $p=0.004$ ) and 6-min walk distance (7.5,  $p=0.006$ ) independently foretold 2-year survival, but modified Medical Research Council dyspnoea score (2.2,  $p=0.14$ ) and forced expiratory volume in 1 s % predicted (0.3,  $p=0.60$ ) did not. Pro-adrenomedullin plus BODE better predicts mortality in COPD patients than does BODE alone; pro-adrenomedullin may substitute for 6-min walk distance in BODE when 6-min walk testing is unavailable.

**Publisher** European Respiratory Society

**ISSN/ISBN** 0903-1936 ; 1399-3003

**edoc-URL** <http://edoc.unibas.ch/55859/>

**Full Text on edoc** No;

**Digital Object Identifier DOI** 10.1183/09031936.00058713

**PubMed ID** <http://www.ncbi.nlm.nih.gov/pubmed/23794469>

**Document type (ISI)** Journal Article, Multicenter Study